ABL1 and leukemia: We found that the mRNA of ABL1 were reduction of HSCs and induction of K562 cells by saracatinib during erythroid differentiation, and our results indicate that saracatinib prompts hemin-induced K562 erythroid differentiation, accompanied by activation of autophagy and increased cell death, which would be a new anti-leukemia strategy using saracatinib.